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thromboxane A2, as reported in our previous manuscript (Mostefai 
et al. 2008). These data demonstrate that IL-10 restores the 
vascular hyporeactivity induced by LPS in tissue-engineered blood 
vessel models.
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Human secreted phospholipases A2 (sPLA2s) represent novel 
attractive therapeutic targets and biomarkers in coronary artery 
diseases (CAD). We have shown that human Group X sPLA2 (hGX 
sPLA2) is present in atherosclerotic lesions and that hGX sPLA2 
modi ed LDL induces foam cell formation. To elucidate whether 
hGX sPLA2 has a causative role in CAD we have screened the human 
PLA2G10 gene to identify frequent polymorphisms, and we have 
examined their possible association with cardiovascular end-points 
and intermediate in ammatory phenotypes in a large prospective 
study of patients with CAD (the AtheroGene study). Although no 
signi cant association was found between the various polymorphisms 
identi ed and lipids or in ammatory markers, patients carriers of the 
C allele of the T-512C polymorphism located in the 5’ untranslated 
region showed a decreased risk of recurrent cardiovascular events. 
Molecular analysis of the only missense variant (R38C) showed its 
functional relevance as it leads to a profound change in expression 
and secretion of hGX sPLA2.
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Objectives — Vascular Cell Adhesion Molecule-1 (VCAM-1) plays 
a major role in the chronic in ammatory processes involved 
in vulnerable atherosclerotic plaque development. It has been 
shown that the technetium-labelled HMC-I derived peptide B2702p 
bound speci cally to VCAM-1 and allowed the ex vivo imaging of 
atherosclerotic lesions in WHHL rabbits. However, B2702p target-
to-background ratio was suboptimal for in vivo imaging of VCAM-1 
expression in atherosclerotic lesions. In order to increase the target 
to background ratio, ten derivatives of B2702p were synthesized 
(B2702p-1 to 10). We hypothesized that technetium radiolabelled 
B2702p derivatives might allow the molecular imaging of VCAM-1 
expression in an experimental model of atherosclerosis.
Material and Methods — A mouse model of focal atherosclerotic 
plaque development induced by left carotid artery ligation in ApoE-
/- mice was used. 99mTc-B2702p (n=9) and 99mTc- B2702p-1 — 10 
(n=3 for each except B2702p-1, n=5, and B2702p-4, n=5) were 
injected intravenously to the anesthetized animals 3 weeks following 
the ligation. Whole-body planar image acquisition was performed 
for 3 hrs with all radiolabelled peptides and SPECT imaging of 6 
additionnal mice was also performed with 99mTc-B2702p-1. The 
animals were then euthanized and the biodistribution evaluated 
by gamma-well counting of excised organs. The expression of 
VCAM-1 in the ligated and contralateral arteries was evaluated by 
immunohistology.
Results — A robust VCAM-1 immunostaining was observed in ApoE-
/- mice in the atherosclerotic lesions at the level of the left carotid 
whereas no VCAM-1 expression was detected in the contralateral 
carotid. Among the ten evaluated peptides, 99mTc-B2702p-1 
exhibited the more favourable properties. By gamma-well counting, 
there was a signi cant 2.0-fold increase in 99mTc-B2702p-1 left-to-
right carotid artery activity ratio (2.61±0.61) and a 3.4-fold increase 
in left carotid-to-blood activity ratio (1.41±0.36) in comparison to 
99mTc-B2702p (1.32±0.23 and 0.41±0.09, respectively, P<0.05 for 
both comparisons). Finally, a higher 99mTc-B2702p-1 activity in 
the left than in the right carotid was observed by SPECT imaging 
(33.3±5.8 vs. 25.1±5.3 cpm/mm²/ID, respectively, P<0.05).
Conclusion — Radiolabelled-B2702p-1 is a potentially useful 
radiotracer for the in vivo molecular imaging of VCAM-1 expression 
in atherosclerotic plaques.
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Objectif — La glycoprotéine VI est le récepteur d’activation 
des plaquettes par les collagènes de type I et de type III. Nous 
avons émis l’hypothèse que nous pourrions développer une sonde 
spéci que du collagène basée sur la spéci cité de GPVI et que cette 
sonde permettrait de visualiser la  brose in vivo par une méthode 
non invasive
Méthodes — Un anticorps bloquant la liaison de GPVI au collagène 
a été utilisé pour cribler une banque peptidique permettant 
d’identi er un motif peptidique cyclique. La capacité du peptide 
à mimer la GPVI a été analysée par des études de liaison et de 
compétition en phase solide. La liaison au collagène tissulaire a 
été analysée par histochimie. L’imagerie in vivo a été réalisée par 
injection du peptide-marqué au Tc-99m dans un modèle de  brose 
cicatricielle sur infarctus du myocarde chez le rat, scintigraphie et 
autoradiographie.
Résultats — Le peptide, nommé collagelin, se lie de manière 
spéci que à l’anticorps anti GPVI 9O12.2 et aux collagènes I et III 
in vitro et la liaison est inhibée par GPVI indiquant que le peptide 
mime GPVI. Cependant le collagelin n’inhibe pas l’agrégation 
des plaquettes induite par le collagène. Les études d’histochimie 
